Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

Blauvelt, A; C Prinz, J; B Gottlieb, A; Kingo, K; Sofen, H; Ruer-Mulard, M; Singh, V; Pathan, R; Papavassilis, C; Cooper, S; Study Group, FEATURE

doi:10.1111/bjd.13348

Public

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

Shared by NobleBlocks on Feb 1, 2015 • 12:00 AM UTC

Authors:

A Blauvelt

J C Prinz

A B Gottlieb

Abstract

BACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection. Self-administration by pre-filled syringe (PFS) can offer patients clinical benefits of a drug, with ...

Discussions